DOMAIN THERAPEUTICS has a total of 41 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in Australia, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are VIROSTATICS SRL, MIRONID LTD and NAD AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 7 | |
#2 | EPO (European Patent Office) | 7 | |
#3 | WIPO (World Intellectual Property Organization) | 7 | |
#4 | Canada | 5 | |
#5 | China | 4 | |
#6 | Israel | 4 | |
#7 | United States | 3 | |
#8 | Brazil | 1 | |
#9 | Japan | 1 | |
#10 | New Zealand | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Medical preparations | |
#5 | Microorganisms | |
#6 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Schann Stephan | 33 |
#2 | Mayer Stanislas | 32 |
#3 | Manteau Baptiste | 14 |
#4 | Giethlen Bruno | 5 |
#5 | Morice Christophe | 5 |
#6 | Blayo Anne-Laure | 5 |
#7 | Dorange Ismet | 5 |
#8 | Stanislas Mayer | 3 |
#9 | Amalric Camille | 3 |
#10 | Stephan Schann | 3 |
Publication | Filing date | Title |
---|---|---|
WO2021064189A2 | Prostaglandin e2 (pge2) ep4 receptor antagonists | |
WO2021023813A1 | 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists | |
WO2020021064A1 | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 | |
EP3000814A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | |
EP2666775A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | |
CA2779073A1 | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | |
EP2210891A1 | New adenosine receptor ligands and uses thereof |